

Enhancing robustness in acute cardiovascular observational studies: evaluating covariate adjustment

Johan Verbeeck  *

Data Science Institute, UHasselt, Agoralaan Building D, 3590 Diepenbeek, Belgium

Online publish-ahead-of-print 12 June 2024

In clinical trials, the primary objective often involves studying the associations between several variables. In randomized clinical trials (RCTs), the focus typically lies on the association between clinical outcomes and two or several treatment options. Conversely, in observational studies, interest extends beyond treatments and may include associations with various patient characteristics (e.g. demographic and disease-specific factors), frequently for predictive or prognostic purposes.

These associations, however, may be subject to influence by external factors, commonly known as confounding factors, which may introduce biases in the conclusions. To mitigate the impact of these confounding factors, appropriate measures should be taken to avoid imbalances. One strategy to eliminate potential bias is to balance subjects across these factors through randomization and stratification. Another approach is to adjust the statistical analyses for these covariates. Although covariate adjustment is not strictly necessary in RCTs, it may enhance efficiency.¹

Covariate adjustment is well studied in RCTs, with available regulatory guidance,^{2,3} although the quality of implementation varies and may be improved.¹ There is also a need to study covariate adjustment in observational studies and to develop guidance documents,⁴ as the requirement to adjust is higher in non-randomized studies. Moreover, the variability in implementation of covariate adjustments is equally, if not more, present in observational studies. The latter is demonstrated by a review of publications in the *European Heart Journal: Acute Cardiovascular Care* over the past 5 years, which included 55 non-randomized studies, representing 62 covariate-adjusted analyses.

In the observational studies, the most commonly used covariate adjustments were multiple or multivariable regression models ($n = 49$; 79%), similar to those in RCTs. These included Cox proportional hazards ($n = 23$; 47%), logistic ($n = 22$; 45%), and linear ($n = 4$; 8%) regression models. Due to the non-randomized nature of observational studies, often more covariates are imbalanced compared with randomized trials and need to be included in these models. Adding numerous covariates in regression models, however, can be cumbersome and may lead to over-fitting, i.e. tailoring the model too much to the available data, thereby reducing generalizability. It is important to note that multiple/multivariable regression models should not be confused with

multivariate models, which aim at modelling multiple clinical outcomes in a multilevel or joint approach.

An alternative method for covariate adjustment, aimed at correcting potential bias rather than examining covariate–outcome associations, is covariate adjustment through propensity scores⁵ ($n = 13$; 21%). These scores, calculated through logistic models, represent the probability of patients belonging to a subgroup given a set of covariates, summarizing all patient characteristics into a single value. Propensity scores reduce the potential for over-fitting and can be used for covariate adjustment through matching, stratification, inverse probability weighting, or as a covariate in a regression model.⁵ Although there is no clear superior method,⁵ matched propensity scores were most commonly used ($n = 8$; 62%), followed by modelling as a covariate ($n = 3$; 23%) and inverse treatment weighting ($n = 2$; 15%). Propensity score matching has the potential disadvantage of excluding unmatched observations. When interpreting treatment effects, it is important to realize that inverse probability weighting and matching estimate marginal treatment effects, whereas multivariable regression and stratification estimate conditional effects.⁵

The methods for selecting covariates for adjustment are another source of variability. Most studies pre-selected covariates based on prior knowledge ($n = 33$; 61%), while some used automated selection procedures ($n = 11$; 20%) or included all covariates with a P -value below a pre-specified threshold in a univariate analysis ($n = 8$; 15%). A few studies selected covariates based on observed imbalances between groups ($n = 2$; 4%). Pre-selecting covariates risk missing important confounders, whereas automated selection procedures may lead to over-fitting. Regardless of the method, the selection procedure should be clearly presented, as in some cases involving automated procedures, it was insufficiently detailed whether a forward or backward selection was used.

Additionally, variation existed in evaluating the validity and robustness of conclusions. Robust conclusions require assessing the validity of the models' implicit assumptions, such as proportional hazards and the form of the association ($n = 4$; 7%). The reliability of conclusions also depends on the absence of the influence of extreme observations ($n = 2$; 4%), which may cause bias, and the absence of multi-collinearity

* Corresponding author. Tel: +32486225679, Email: johan.verbeeck@uhasselt.be

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Table 1 Recommendations for covariate adjustment in observational studies

Recommendations for observational studies
Be transparant about the variable selection method
• Motivation of pre-specified variables • Detail automated selection procedure (forward, backward, which in-exclusion criteria) • Detail threshold in a univariate analysis for inclusion
Select the appropriate covariate adjustment method for your purpose
• Regression model: • Allows for identifying prognostic/predictive covariates • Be mindful of potential over-fitting, which leads to bias • Be mindful of the correct functional form • Covariates measured after treatment should not be included • Propensity score: • Does not allow for identifying prognostic/predictive covariates • Baseline covariates should be included irrespective of univariate significance with outcome or collinearity. • Covariates measured after treatment should not be included
Add sensitivity analyses for robustness of the results
• Vary method for covariate adjustment • Vary variable selection method • Vary number of covariates
Evaluate the validity of the results
• Assess validity of model assumptions (proportional hazards, functional form, ...) • Assess influence of extreme observations • Assess multi-collinearity
Detail handling of multiplicity
Detail handling of missing data

($n = 6$; 11%), which can increase variability and decrease efficiency. Confirming results through sensitivity analyses ($n = 14$; 26%), by varying covariate selection procedures^{6,7} or adjustment methods,^{6,8} also enhances robustness. Notice that when multiple analyses are performed in an exploratory observational trial, handling multiplicity is crucial, even though conclusions from observational studies are generally hypothesis

generating, especially when based on single-centre or single-country databases.

Finally, variation was observed in handling missing data ($n = 7$; 13%). Missing data may lead to biased conclusions, and the mechanism of missingness may be complex for observational studies. Approaches applied to deal with missing data included multiple imputations ($n = 6$; 11%) and worst-case/best-case scenarios ($n = 1$; 2%).

In the context of acute cardiovascular trials, observational studies are conducted frequently, which require covariate adjustments for unbiased results. However, current practice of covariate adjustment varies. There is a need for further methodological investigation and the development of guidance on covariate adjustment for non-randomized studies (Table 1).

Funding

None declared.

Conflict of interest: None declared.

Data availability

There are no new data associated with this article.

References

1. Pironcini L, Gregson J, Owen R, Collier T, Pocock S. Covariate adjustment in cardiovascular randomized controlled trials: its value, current practice, and need for improvement. *JACC Heart Fail* 2022;**10**:297–305.

2. Food and Drug Administration. Adjusting for covariates in randomized clinical trials for drugs and biologics with continuous outcomes guidance for industry. <https://www.fda.gov/media/148910/download> (4 June 2024). (2021).

3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) guideline on adjustment for baseline covariates in clinical trials. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adjustment-baseline-covariates-clinical-trials_en.pdf (4 June 2024). (2015).

4. Food and Drug Administration. Adjusting for covariates in randomized clinical trials for drugs and biologics with continuous outcomes guidance for industry. <https://www.fda.gov/media/177128/download> (4 June 2024). (2024).

5. Elze MC, Gregson J, Baber U, Williamson E, Sartori S, Mehran R, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. *J Am Coll Cardiol* 2017;**69**:345–357.

6. Rathod KS, Jain AK, Firoozi S, Lim P, Boyle R, Nevett J, et al. Outcome of inter-hospital transfer versus direct admission for primary percutaneous coronary intervention: an observational study of 25,315 patients with ST-elevation myocardial infarction from the London heart attack group. *Eur Heart J Acute Cardiovasc Care* 2020;**9**:948–957.

7. Ekerstad N, Javadzadeh D, Alexander KP, Bergström O, Eurenus L, Fredrikson M, et al. Clinical Frailty Scale classes are independently associated with 6-month mortality for patients after acute myocardial infarction. *Eur Heart J Acute Cardiovasc Care* 2022;**11**: 89–98.

8. Bataille V, Ferrières J, Danchin N, Puymirat E, Zeller M, Simon T, et al. Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: data from the FAST-MI 2005 registry. *Eur Heart J Acute Cardiovasc Care* 2019;**8**:218–230.